How can this work across different treatments?

We treat with different ICI in the lab. About 80% of what we have done to date is aPD-1 (Pembrolizumab biosimilar), about 15% is aPD-1+aCTLA-4 (Ipilimumab-Nivolumab biosimilar combination, and the remaining 5% is aPD-L1. A few samples have been treated with aPD-L1+aCTLA-4(Durvalumab-Tremelimumab biosimilar combo). We believe that by looking at the cytokine response from a functional assessment, we are able to capture the immune cells in the sample "talking" to and recruiting other immune components, therefore allowing for assessment across immune-relevant modalities. So far, we see similar immune profiles across treatment types, though like we said, it is only ~15% of our data, so more is needed to confirm.